Upregulation of MAD2L1 mediated by ncRNA axis is associated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma: A review

Medicine (Baltimore). 2023 Jan 13;102(2):e32625. doi: 10.1097/MD.0000000000032625.

Abstract

Background: The mortality rate and prognosis of patients with hepatocellular carcinoma (HCC) are well known. A variety of highly malignant human cancers express mitotic arrest deficient 2 like 1 (MAD2L1), a transcription factor that plays a critical role in their development and progression. However, MAD2L1's particular mechanisms and effects on HCC remain uncertain.

Methods: We performed a pan-cancer analysis for MAD2L1 prognosis and expression using The Cancer Genome Atlas and Genotype-Tissue Expression data in the present study. MAD2L1 may act as an oncogene in HCC, and a combination of in silico analyses, including expression, survival, and correlation analyses, were performed to identify non-coding ribonucleic acids (ncRNAs) that contribute to MAD2L1 overexpression.

Results: In conclusion, MAD2L1 is most likely regulated by HCP5/miRNA-139-5p/MAD2L1 in HCC based on its upstream ncRNA-related pathway. A significant positive association was also found between MAD2L1 levels and tumor immune cell infiltration, immune cell biomarkers, and immune checkpoint expression.

Conclusion: Our findings demonstrate that ncRNA-mediated upregulation of MAD2L1 in HCC is closely related to poor prognosis and tumor infiltration.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Carcinoma, Hepatocellular* / genetics
  • Humans
  • Liver Neoplasms* / genetics
  • Mad2 Proteins / genetics
  • MicroRNAs*
  • Oncogenes
  • Prognosis
  • RNA, Untranslated
  • Transcriptional Activation
  • Up-Regulation

Substances

  • RNA, Untranslated
  • Biomarkers, Tumor
  • MAD2L1 protein, human
  • Mad2 Proteins
  • MIRN139 microRNA, human
  • MicroRNAs